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Abstract
Up-regulation of proinflammatory cytokines and chemokines in brain (“neuroinflammation”) 
accompanies neurological disease and neurotoxicity. Previously, we documented a striatal 
neuroinflammatory response to acute administration of a neurotoxic dose of methamphetamine 
(METH), i.e. one associated with evidence of dopaminergic terminal damage and activation of 
microglia and astroglia. When we used minocycline to suppress METH-induced 
neuroinflammation, indices of dopaminergic neurotoxicity were not affected, but suppression of 
neuroinflammation was incomplete. Here, we administered the classic anti-inflammatory 
glucocorticoid, corticosterone (CORT), in an attempt to completely suppress METH-related 
neuroinflammation. METH alone caused large increases in striatal proinflammatory cytokine/
chemokine mRNA and subsequent astrocytic hypertrophy, microglial activation, and 
dopaminergic nerve terminal damage. Pre-treatment of mice with acute CORT failed to prevent 
neuroinflammatory responses to METH. Surprisingly, when mice were pre-treated with chronic 
CORT in the drinking water, an enhanced striatal neuroinflammatory response to METH was 
observed, an effect that was accompanied by enhanced METH-induced astrogliosis and 
dopaminergic neurotoxicity. Chronic CORT pre-treatment also sensitized frontal cortex and 
hippocampus to mount a neuroinflammatory response to METH. Because the levels of chronic 
CORT used are associated with high physiological stress, our data suggest that chronic CORT 
therapy or sustained physiological stress may sensitize the neuroinflammatory and neurotoxicity 
responses to METH.
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Neuroinflammation has been associated with a variety of neurological diseases (for a review 
see: Prinz et al. 2011) and with neurotoxicant-induced damage to the CNS (for reviews see: 
Block et al. 2007; Sriram and O’Callaghan 2007; Kraft and Harry 2011). Whether these 
proinflammatory responses represent causes or consequences of neural damage have yet to 
be elucidated (Graeber and Streit 2010; Streit 2010). Substituted amphetamines are one class 
of compounds known to cause neurotoxicity (for reviews see: Bowyer and Holson 1995; 
O’Callaghan and Miller 2005; Riddle et al. 2006; Gudelsky and Yamamoto 2008; Krasnova 
and Cadet 2009; Silva et al. 2010; Yamamoto et al. 2010). For example, methamphetamine 
(METH) causes damage to dopaminergic nerve terminals in the striatum, as evidenced by 
loss of tyrosine hydroxylase (TH) and dopamine (DA), and an accompanying astrogliosis 
and silver degeneration staining (Ellinwood and Escalante 1970; Seiden et al. 1976; 
Hotchkiss et al. 1979; Bowyer et al. 1994; Miller and O’Callaghan 1994; O’Callaghan and 
Miller 1994, 2005; Bowyer and Holson 1995; Ladenheim et al. 2000; Thomas et al. 2004b; 
Fleckenstein et al. 2007; Krasnova and Cadet 2009). A potential role for neuroinflammation 
in these neurotoxic effects has been evaluated only recently (Thomas et al. 2004a,b; Sriram 
et al. 2006). For example, early in the time course of METH-induced damage, we and others 
(LaVoie et al. 2004; Thomas et al. 2004a,b; Kuhn et al. 2006; Sriram et al. 2006) observed 
elevations in proinflammatory cytokines and chemokines in striatum, findings consistent 
with microglial activation in the target region. Suppression of this proinflammatory response 
by pre-treating with minocycline did not affect METH-induced dopaminergic neurotoxicity 
and astrogliosis (Sriram et al. 2006), findings that argued for a consequence rather than a 
causal role of neuroinflammation in METH neurotoxicity. Nevertheless, the enhanced 
expression of key proinflammatory mediators implicated in neural damage, e.g. Tumor 
necrosis factor (TNF)-α (Sriram and O’Callaghan 2007; Tansey et al. 2007; McCoy and 
Tansey 2008), was not completely blocked by pre-treatment with minocycline prior to 
METH (Sriram et al. 2006). Therefore, the possibility remains for a role of 
neuroinflammation in METH neurotoxicity.
In this investigation, an effort was made to achieve a greater reduction in the 
neuroinflammation caused by METH exposure by acute and chronic pre-treatment with the 
classic anti-inflammatory glucocorticoid, corticosterone (CORT). While acute CORT pre-
treatment was able to dampen some of the METH-induced inflammation; chronic (1-week) 
pre-treatment with CORT in the drinking water caused greatly exacerbated expression of 
proinflammatory cytokines and chemokines in target and non-target regions. This elevation 
of neuroinflammation was accompanied by greater gliosis and dopaminergic nerve terminal 
damage. These findings suggest that chronic exogenous CORT and, perhaps, persistent high 
physiological stress levels of endogenous CORT, can sensitize the CNS to 
neuroinflammatory and neurotoxic effects of METH.
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The following drugs and chemicals were kindly provided by or obtained from the sources 
indicated: d-METH (Sigma Chemical Co., St. Louis, MO, USA), CORT (Steraloids, Inc., 
Newport, RI, USA) and bicinchoninic acid protein assay reagent, and bovine serum albumin 
(Pierce Chemical Co., Rockford, IL, USA). The materials used in the Glial fibrillary acidic 
protein (GFAP) assay have been described in detail (O’Callaghan 1991, 2002). The 
materials used in the TH immunoassay have been described previously (O’Callaghan et al. 
1990; Sriram et al. 2004, 2006). All other reagents and materials were of at least analytical 
grade and were obtained from a variety of commercial sources.
Animals
Male C57BL/6J mice (n = 5 mice per group) 4–6 weeks of age were purchased from 
Jackson Labs (Bar Harbor, ME, USA). All procedures were performed under protocols 
approved by the Institutional Animal Care and Use Committee of the Centers for Disease 
Control and Prevention, National Institute for Occupational Safety and Health, and the 
animal colony was certified by the American Association for Accreditation of Laboratory 
Animal Care. Upon receipt, the mice were housed individually in a temperature-controlled 
(21 ± 1°C) and humidity-controlled (50 ± 10%) colony room maintained under filtered 
positive-pressure ventilation on a 12-h light/12-h dark cycle beginning at 0600 EDT. The 
plastic tub cages were 46 cm in length by 25 cm in width by 15 cm in height; cage bedding 
consisted of heat-treated pine shavings spread at a depth of approximately 4 cm. Food 
(Purina rat/mouse chow) and water were available ad libitum.
Dosing
Acute CORT was given as a single s.c. dose of 20 mg/kg 30 min prior to METH (20 mg/kg, 
s.c.) or vehicle (saline 0.9%) treatment. Chronic CORT was given in the drinking water (400 
mg/L in 1.2% EtOH) for 1 week prior to METH (20 mg/kg, s.c.) or vehicle (saline 0.9%) 
treatment. The latter regimen of CORT was chosen to mimic high physiological stress levels 
of this hormone, levels known to cause immunosuppression as evidenced by marked 
involution of the thymus (e.g. O’Callaghan et al. 1991). Mice were killed by decapitation at 
12 or 72 h post METH or vehicle injection. These time points correspond to peak increases 
in expression of proinflammatory cytokines and astrogliosis, respectively, following 
administration of METH (Sriram et al. 2006).
Core temperature
Rectal temperature was recorded with a Bat-10 thermometer coupled to a RET-3 mouse 
rectal probe (Physitemp, Inc., Clinton, NJ, USA) lubricated with mineral oil as described 
previously (Miller and O’Callaghan 1994).
Brain preparation for immunohistochemistry
At 72 h post METH or vehicle injection, mice were anesthetized with sleep away (0.1 mL; 
Fort Dodge Animal Health, Fort Dodge, IA, USA) and transcardially perfused with 0.9% 
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saline followed by 10% formalin. The brains were then removed, placed in 10% formalin, 
and kept at 4°C until processed for immunohistochemistry.
Histochemistry and immunohistochemistry
Coronal sections 40-μm thick were cut and collected in 2% formaldehyde with 0.1 M 
sodium phosphate buffer and stored at 4°C until processing. To visualize dopamine-
containing neurons and processes, TH immunolabel was detected using a rabbit antiserum to 
TH (1 : 2000; Chemicon, Temecula, FL, USA) diluted in 0.1 M phosphate buffer with 0.3% 
Triton-X. This signal was amplified using the avidin and biotinylated horseradish peroxidase 
macromolecular complex (ABC; Vector Laboratories, Burlingame, CA, USA), and 
visualized with 0.4 mg/mL of 3,3′-diaminobenzidine (DAB) in 50 mM Tris buffer. Images 
were obtained using a SenSys cooled CCD digital camera mounted on a Nikon Eclipse E400 
light/epifluorescent microscope and MetaView Imaging Software (advanced Scientific, Inc., 
Meraux, LA, USA). The isolectin B4-procedure of Streit (1990) was used to label microglia. 
Sections were incubated overnight at 4°C in a solution of B4 isolectin from 
Griffoniasimplicifolia (10 μg/mL; Sigma) coupled to horseradish peroxidase, and the 
binding sites were visualized with DAB and H2O2. GFAP immunolabel was detected using 
a rabbit antiserum to GFAP (1 : 1000; DAKO) overnight at 4°C, and then the ABC method 
and DAB were applied as described above.
Brain dissection and tissue preparation
Immediately after decapitation, whole brains were removed from the skull with the aid of 
blunt curved forceps. Striatum, hippocampus, and frontal cortex (includes motor, insular, 
and pyriform cortex) were dissected free hand on a thermoelectric cold plate (Model TCP-2, 
Aldrich Chemical Co., Milwaukee, WI, USA) using a pair of fine curved forceps (Roboz, 
Washington, DC, USA). Brain regions from one side of the brain were frozen at −85°C and 
used for subsequent isolation of total RNA; brain regions from the other side of the brain 
were used for total and specific protein analysis. These regions were weighed, homogenized 
with a sonic probe (model XL-2005, Heat Systems, Farmingdale, NY, USA) in 10 volumes 
of hot (90–95°C) 1% sodium dodecyl sulfate, and stored frozen at −70°C before total protein 
assay and immunoassay of GFAP and TH. A separate set of mice were used to generate 
striatal sample for analyses of dopamine and metabolites.
RNA isolation, cDNA synthesis, and real-time PCR amplification
Total RNA from striatum, hippocampus, and cortex were isolated using Trizol® reagent 
(Invitrogen, Grand Island, NY, USA) and Phase-lock heavy gel (Eppendorf AG, Hamburg, 
Germany). The RNA was further cleaned using RNeasy mini spin column (Qiagen, 
Valencia, CA, USA). Total RNA (1 μg) was reverse transcribed to cDNA using 
SuperScript™ II RNase H− and oligo (dT)12-18 primers (Invitrogen) in a 20 μL reaction. 
Real-time PCR analysis of Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), TNF-α, 
IL-6, CCL-2, IL-1β, Leukemia inhibitory factor (LIF), and Oncostatin M (OSM) was 
performed in an ABI PRISM 7700 sequence detection system (Applied Biosystems, 
Carlsbad, CA, USA) in combination with TaqMan® chemistry. Specific primers and dual-
labeled internal fluorogenic (FAM/TAMRA) probe sets (TaqMan® Gene Expression 
Assays) for these genes were procured from Applied Biosystems and used according to the 
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manufacturer’s recommendations. All PCR amplifications (40 cycles) were performed in a 
total volume of 50 μL, containing 1 μL cDNA, 2.5 μL of the specific Assay of Demand 
primer/probe mix, and 25 μL of Taqman® Universal master mix. Sequence detection 
software (version 1.7; Applied Biosystems) results were exported as tab-delimited text files 
and imported into Microsoft Excel for further analysis. Relative quantification of gene 
expression was performed using the comparative threshold (CT) method as described by the 
manufacturer (Applied Biosystems; User Bulletin 2). Changes in mRNA expression levels 
were calculated after normalization to Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). The ratios obtained after normalization are expressed as fold change over 
corresponding saline-treated controls.
Protein assay
Total protein was determined by the bicinchoninic acid method (Smith et al. 1985) using 
bovine serum albumin as standard.
GFAP and TH assays
GFAP was assayed in accordance with a previously described procedure (O’Callaghan 
1991, 2002). In brief, a rabbit polyclonal antibody to GFAP was coated on the wells of 
Immulon-2 microliter plates (Thermo Labsystems, Franklin, MA). The sodium dodecyl 
sulfate homogenates and standards were diluted in phosphate-buffered saline (pH 7.4) 
containing 0.5% Triton X-100. After blocking non-specific binding with 5% non-fat dry 
milk, aliquots of the homogenate and standards were added to the wells and incubated. 
Following washes, a mouse monoclonal antibody to GFAP (1 : 400; DAKO, Carpenteria, 
CA, USA) was added to ‘sandwich’ the GFAP between the two antibodies. An alkaline 
phosphatase-conjugated antibody directed against mouse IgG was then added and a colored 
reaction product was obtained by subsequent addition of the enzyme substrate p-nitrophenol. 
Quantification was achieved by spectrophotometry of the colored reaction product at 405 
nm in a microplate reader, Spectra Max Plus, and analyzed using Soft Max Pro Plus 
software (Molecular Devices, Sunnyvale, CA, USA). The amount of GFAP in the samples 
was calculated as micrograms GFAP per milligram total protein.
TH holoenzyme protein was assessed using a fluorescence-based ELISA developed in the 
laboratory (Sriram et al. 2004). The protocol was essentially similar to that for the GFAP 
assay except that a mouse monoclonal antibody to TH (1 : 400; Sigma) was used as the plate 
capture antibody and a rabbit polyclonal antibody was used to ‘sandwich’ TH protein. The 
amount of sandwich antibody bound to TH was then detected using a peroxidase-labeled 
antibody directed against rabbit IgG. Peroxidase activity was detected using the fluorogenic 
substrate Quantablu (Pierce), which has excitation and emission maxima of 325 and 420 nm, 
respectively (read at 320/405 nm). The amount of TH in the samples was calculated and 
expressed as micrograms TH per milligram total protein.
Analysis of dopamine and metabolites
Dopamine and its metabolites were quantified by high-performance liquid chromatography 
with electrochemical detection (HPLC-EC; Waters) using the method detailed in Nishi et al. 
(2008). Briefly, tissues were homogenized in 300 μL of ice-cold 0.2 M perchloric acid, 
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containing 1 um dihydroxybenzylamine as internal standard, and centrifuged at 10 000 g for 
10 min at 4°C. The supernatant was filtered through a 0.2 μm membrane, and an aliquot (10 
μL) was injected from a temperature-controlled (4°C) automatic sample injector 
(Waters717plus autosampler) connected to a Waters 515 HPLC pump, and catecholamines 
were separated on a C18 reverse-phase column (LC-18 RP; Waters SYMMETRY, 25 cm × 
4.6 mm; 5 μm) and electrochemically detected (Waters 464 Pulsed Electrochemical 
Detector, Waters, Milford, MA, USA) and analyzed using Millennium software (Waters). 
Recovery of each analyte was adjusted with respect to the internal standard and quantified 
from a standard curve. The levels of dopamine and its metabolites were expressed as 
micrograms per gram of wet tissue.
Statistics
Statistical analysis of data was performed utilizing SigmaPlot (v 11.0). Core temperature 
data were analyzed using a three-way analysis of variance (ANOVA). PCR data were 
analyzed using a two-way ANOVA. GFAP and TH protein concentration was analyzed 
using one-way ANOVA. All ANOVAs were followed by Student-Newman–Keul’s post hoc 
test for multiple comparisons.
Results
Chronic CORT Enhances METH-induced Expression of Some Proinflammatory Cytokines/
Chemokines in Striatum
In agreement with our previous findings, a single dose of METH results in enhanced 
expression of mRNA for a variety of proinflammatory cytokines and chemokines in the 
mouse striatum at 12 h post dosing (Fig. 1). These effects of METH alone range from 2.5-
fold for IL-6 to over 130-fold for LIF. When we attempted to suppress these effects by pre-
treating with an acute anti-inflammatory dose of CORT, we were largely unsuccessful. Only 
the METH-induced expression of CCL-2 and OSM were reduced by pre-treatment with 
CORT with the maximum suppression reaching only a 40% decrease of the METH-induced 
increase in OSM.
We reasoned that a more sustained anti-inflammatory pre-treatment would be required to 
suppress or block the METH-induced expression of proinflammatory mediators. Therefore, 
we administered CORT in the drinking water for a week prior to administration of METH. 
This CORT regimen was known to be immunosuppressive as evidenced by thymic 
involution, suggesting that this pre-treatment should be sufficient to attenuate expression of 
proinflammatory mediators. While we did observe a slight attenuation of METH-induced 
expression of TNF-α and OSM by chronic CORT administration, surprisingly, the dominant 
effect of this regimen was to markedly exacerbate the proinflammatory effects of METH at 
12 h post dosing (Fig. 1). The expression of CCL-2, IL-1β, and LIF in the chronic CORT/
METH groups reached 67-, 37-, and 537-fold, respectively. As proinflammatory cytokines 
and chemokines are released by activated microglia and astroglia, our unexpected findings 
for the combination of chronic CORT administration with METH prompted us to examine 
the activation of microglia and astroglia following the chronic CORT/METH exposure.
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Chronic CORT enhances METH-induced activation of microglia in striatum
Isolectin B staining of activated microglia in the striatum is shown in Figure 2. Enhanced 
Isolectin B staining is known to reflect an activated state of microglia associated with 
neuropathology (Streit and Kreutzberg 1987; Kreutzberg 1996). At 72 h post dosing, METH 
alone (panel c) activated few microglia, whereas pre-treatment with chronic CORT greatly 
enhanced the activation of microglia because of METH (panel d).
Chronic CORT enhances METH-induced astrogliosis in striatum
GFAP immunoassay and immunohistochemistry were used to assess striatal astrogliosis 
quantitatively and qualitatively, respectively. In agreement with our previous findings (e.g. 
Sriram et al. 2006), METH administration increased striatal concentration of GFAP by over 
4-fold at 72 h post dosing (Fig. 3a and b). Acute pre-treatment with CORT (20 mg/kg) did 
not affect the METH-induced increase in GFAP (Fig. 3a), whereas pre-treatment with 
chronic CORT greatly enhanced (to eight-fold) the increase in GFAP because of METH 
(Fig. 3b). Neither acute nor chronic CORT alone affected the concentration of GFAP in 
striatum (data not shown).
Consistent with the known low-level expression of GFAP in striatum relative to other brain 
areas (Martin and O’Callaghan 1995), very few astrocytic profiles were seen by 
immunohistochemistry of GFAP in saline or CORT control groups. METH administration 
resulted in the appearance of numerous astrocytic profiles based on GFAP immunostaining 
(Fig. 3e). Pre-treatment with chronic CORT increased the size of astroglial somata and 
processes because of METH (Fig. 3). Thus, GFAP immunoassay and immunohistochemistry 
data are consistent and confirm that chronic CORT pre-treatment exacerbates METH-
induced astrogliosis (panel f). The presence of astrogliosis is indicative of underlying neural 
damage (O’Callaghan and Sriram 2005) and, in the case of METH; it is consistent with 
dopaminergic nerve terminal damage in striatum. Therefore, the results obtained for GFAP 
were suggestive of enhanced METH-induced dopaminergic neurotoxicity following pre-
treatment with chronic CORT.
Chronic CORT enhances METH-induced dopaminergic neurotoxicity in striatum
TH immunoassay and immunohistochemistry were used to assess striatal dopaminergic 
neurotoxicity quantitatively and qualitatively, respectively. In agreement with our previous 
findings (e.g. Sriram et al. 2006), METH administration decreased striatal concentration of 
TH by greater than 25% at 72 h post dosing (Fig. 4a and b). Acute pre-treatment with CORT 
(20 mg/kg) did not affect the METH-induced decrease in TH (Fig. 4a), whereas pre-
treatment with chronic CORT greatly enhanced (to 10% of control) the decrease in TH 
because of METH (Fig. 4b). Neither acute nor chronic CORT alone affected the 
concentration of TH in striatum (data not shown).
METH administration resulted in decreased striatal TH immunostaining, consistent with 
damage to dopaminergic nerve terminals in this brain region (Fig. 4e). Pre-treatment with 
chronic CORT enhanced the decrements in TH immunostaining in striatum (Fig. 4f). Thus, 
TH immunoassay and immunohistochemistry data are consistent and suggest that chronic 
CORT pre-treatment exacerbates METH-induced dopaminergic neurotoxicity (panel f), 
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results in strong agreement with the data already obtained for GFAP levels and staining (Fig. 
3b and f). The decrements in TH seen with METH alone and with prior treatment with 
chronic CORT also were reflected in corresponding decrements in striatal dopamine levels 
(data not shown).
Chronic CORT sensitizes the hippocampus to METH-induced expression of 
proinflammatory cytokines/chemokines
We explored the possibility that the effects of chronic CORT pre-treatment prior to METH 
might be extended to brain regions outside the striatum. Chronic CORT treatment alone did 
not affect cytokine and chemokine expression in the hippocampus, except for IL-6, which 
was reduced by over 50% (Fig. 5). At 12 h post dosing, METH treatment alone did not 
cause a change in proinflammatory cytokine or chemokine expression in the hippocampus, 
findings consistent with a lack of METH-induced damage to this region using this dosing 
regimen. In contrast, mice pre-treated with chronic CORT and given METH showed very 
large increases in mRNA expression for most of the cytokines/chemokines examined. TNF-
α, CCL-2, IL-1β, LIF, and OSM showed 15-, 15-, 40-, 3- and 4.5-fold increases, 
respectively, compared with METH alone or with chronic CORT alone. IL-6 mRNA 
expression was elevated in the chronic CORT and METH-treated group as well, but only in 
comparison with the chronic CORT-treated controls. Together these data show that chronic 
CORT pre-treatment sensitizes the hippocampus to mount a proinflammatory response to 
METH, findings suggestive of activation of microglia and astrocytes.
Chronic CORT sensitizes the hippocampus to METH-induced activation of microglia
Isolectin B staining of microglia in the hippocampus is shown in Figure 6. Neither chronic 
CORT alone, nor METH alone at 72 h post dosing caused a change in microglial staining in 
comparison to saline controls. However, when mice were pre-treated with chronic CORT 
and then given METH, there was an increase in activated microglia in multiple layers of the 
hippocampus (Fig. 6d). In Figure 6e–h and i–l, the CA1 and dentate gyrus (DG) regions, 
respectively, have been enlarged to show the activated microglia in these regions as a 
function of chronic CORT pre-treatment and METH exposure.
Chronic CORT sensitizes the hippocampus to METH-induced astrogliosis
GFAP immunostaining of astrocytes in the hippocampus is shown in Figure 7. Neither 
chronic CORT alone, nor METH alone at 72 h post dosing, caused a change in astrocyte 
staining in comparison to saline controls. However, when mice were pre-treated with 
chronic CORT and then given METH, there was evidence of astrocytic hypertrophy in 
multiple layers of the hippocampus (Fig. 7d). In Figure 7e–h and i–l, the CA1 and dentate 
gyrus (DG) regions, respectively, have been enlarged to show the hypertrophied astrocytes 
in these regions as a function of chronic CORT pre-treatment and METH exposure. Because 
microglial activation and astrocytic hypertrophy often occur at sites of CNS damage, these 
data suggest that chronic CORT pre-treatment prior to METH results in underlying damage 
to the hippocampus.
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Chronic CORT sensitizes the frontal cortex to METH-induced expression of 
proinflammatory cytokines/chemokines
The piriform and frontal cortex have been implicated as a target for subtle neurotoxic effects 
of METH (Schmued and Bowyer 1997; Bowyer et al. 1998, 2004a), therefore, we evaluated 
the effects of chronic CORT pre-treatment prior to METH in these brain regions (Figs 8 and 
9). Chronic CORT treatment alone did not affect cytokine and chemokine expression in the 
frontal cortex, except for IL-6, which was reduced by over 50% (Fig. 8). At 12 h post 
dosing, METH treatment alone did not cause a change in proinflammatory cytokine or 
chemokine expression in the frontal cortex, findings indicative of a lack of METH-induced 
damage to this region using our dosage regimen. In contrast, mice pre-treated with chronic 
CORT and given METH showed very large increases in mRNA expression for most of the 
cytokines/chemokines examined. TNF-α, CCL-2, IL-1β, LIF, and OSM showed 38-, 72-, 
35-, 62-, and 3-fold increases, respectively, compared with METH alone or with chronic 
CORT alone. IL-6 mRNA expression was elevated in the chronic CORT and METH-treated 
group as well, but only in comparison with the chronic CORT-treated controls. As with our 
findings for hippocampus, these data show that chronic CORT pre-treatment sensitizes the 
frontal cortex to mount a proinflammatory response to METH, findings suggestive of 
activation of microglia and astrocytes
Chronic CORT sensitizes the piriform cortex to METH-induced microglial activation and 
astrogliosis
Isolectin B staining (a–d) and GFAP immunoreactivity (e–h) in the piriform cortex are 
shown in Figure 9. These images clearly show the activation of microglia (d) and astrocytic 
hypertrophy (h) caused by chronic CORT pre-treatment on the effects of METH at 72 h post 
dosing.
Chronic CORT does not affect METH-induced increase in core temperature
Variations in core temperature can have a marked influence on METH-induced 
neurotoxicity (Bowyer et al. 1992, 1994; Miller and O’Callaghan 1994; Bowyer and Holson 
1995; O’Callaghan and Miller 2005). To determine if core temperature played a role in the 
effects observed in the present investigation, we examined the effects of CORT pre-
treatment on METH-induced hyperthermia. Core temperature was measured via rectal probe 
at 0, 1, 3, 5, 7, 9, and 24 h (Fig. 10). METH administration alone caused the expected 
increase in core temperature and CORT pre-treatment alone also caused a slight rise in core 
temperature based on area under the curve analysis. The increase in core temperature 
because of METH was not augmented by prior treatment with CORT.
Discussion
Damage to the CNS results in activation of microglia and astrocytes at sites of injury 
(Kreutzberg 1996; Eng et al. 2000; Norenberg 2005; O’Callaghan and Sriram 2005; 
Sofroniew 2005, 2009; Streit 2005). These cellular responses often are accompanied by 
enhanced expression of proinflammatory mediators, i.e., neuroinflammation (Prinz et al. 
2011). Microglial and astroglial activation and the elaboration of proinflammatory cytokines 
and chemokines occur in conjunction with METH-induced damage to striatal dopaminergic 
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nerve terminals (Thomas et al. 2004a; Sriram et al. 2006). These observations are consistent 
with glial activation and neuroinflammatory responses to METH neurotoxicity. Because 
these findings also raised the possibility of a contribution of neuroinflammation to METH 
neurotoxicity, we attempted to suppress neuroinflammatory responses to METH using pre-
treatment with the anti-inflammatory tetracycline derivative, minocycline (Sriram et al. 
2006). While we were able to dampen the expression of multiple cytokines and chemokines 
using this approach, METH-induced dopaminergic terminal damage and accompanying 
astrogliosis were not affected (Sriram et al. 2006). Because suppression of 
neuroinflammation was incomplete using minocycline, here we turned to acute and chronic 
administration of the anti-inflammatory glucocorticoid, CORT, as a potentially more 
effective means of blocking proinflammatory responses to METH. Acute pre-treatment with 
CORT was not effective in completely suppressing METH-associated neuroinflammation. 
More surprisingly, however, pre-treatment with chronic high physiological levels of CORT 
resulted in a marked proinflammatory rather than an anti-inflammatory response to METH-
associated neuroinflammation. Moreover, this exaggerated inflammation because of chronic 
CORT pre-treatment was associated with exacerbated glial responses and exacerbated 
damage to striatal dopaminergic nerve terminals, deficits that approached those seen in 
models of Parkinson’s Disease (Jackson-Lewis and Przedborski 2007).
By surveying the expression of mRNA for key proinflammatory cytokines and chemokines, 
we confirmed that even a single dose of METH (20 mg/kg) results in striatal 
neuroinflammation involving multiple proinflammatory mediators. As we previously 
observed for pre-treatment with minocycline (Sriram et al. 2006), TNF-α also remained 
resistant to suppression following pre-treatment with acute CORT. Moreover, with the 
exception of minor suppression of expression of CCL-2 and OSM, none of the METH-
induced inflammatory mediators were altered by CORT. These findings with acute CORT 
pre-treatment followed by METH stand in contrast to those observed with acute pre-
treatment with CORT followed by administration of the known inflammogen, 
lipopolysaccharide (LPS). LPS-induced neuroinflammation, brain wide, was markedly 
attenuated by acute CORT pre-treatment (Kelly et al. 2011). These distinctions between the 
effects of acute CORT on METH versus LPS-related neuroinflammation suggest that the 
former involves damage-related microglial activation resistant to anti-inflammatory therapy, 
whereas the latter involves an acute phase response amenable to the anti-inflammatory 
effects of CORT.
By moving to chronic administration of CORT in the drinking water, we felt that a more 
sustained immunosuppression offered a better means to prevent striatal neuroinflammatory 
responses to METH. Not only did the week-long pre-treatment with CORT either fail (IL-6) 
or only marginally suppress (TNF-α, OSM) the expression of cytokines induced by METH, 
but extraordinarily large enhancements in METH-related cytokine (IL-1β, LIF) and 
chemokine (CCL-2) expression were caused by chronic CORT. Thus, the classic anti-
inflammatory agent served as a proinflammatory stimulus for METH-related 
neuroinflammation. These data emphasize the complex nature of the regulation of 
proinflammatory responses to CNS injury (Sriram et al. 2006; O’Callaghan et al. 2008), as 
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with systemic inflammogens (Frank et al. 2010), against a background of chronic immune 
suppression (Dhabhar 2009).
In the CNS, microglial activation is the most widely recognized cellular response associated 
with neuroinflammation (Kreutzberg 1996; Graeber and Streit 2010; Streit 2010; Prinz et al. 
2011). Staining for activated microglia with isolectin confirmed such activation in striatum 
with METH alone and, consistent with qPCR data for IL-1β, LIF, and CCL-2, microglial 
activation was markedly enhanced with chronic CORT pre-treatment prior to METH. 
Activation of microglia and the enhanced expression of proinflammatory mediators 
constitute components of an acute phase response to systemic inflammation (Quan et al. 
1999), effects distinct from, and that do not require, underlying CNS damage. Moreover, as 
we observed previously (Sriram et al. 2006), suppression of neuroinflammation by 
minocycline administration prior to METH does not protect against dopaminergic terminal 
loss or the induction of astrogliosis, two key features of METH neurotoxicity. Therefore, 
enhanced neuroinflammation and microglial activation because of chronic CORT prior to 
METH did not necessarily predict enhanced damage to dopaminergic terminals and 
accompanying enhancement of astrogliosis. The fact that we indeed did observe a linkage 
among enhanced microglia activation, enhanced astroglial activation, and increased damage 
to dopaminergic terminals because of chronic (but not acute) CORT suggested that the 
neuroinflammatory component of these responses constituted elements of a damage 
response. Thus, the priming/sensitization caused by chronic CORT appears to involve neural 
damaging aspects of neuroinflammation distinct from those merely associated with acute 
phase responses (Sugama et al. 2009; Frank et al. 2010). The mechanisms through which 
CORT acts chronically to exert a proinflammatory effect in the intact or injured CNS have 
been proposed (Sorrells et al. 2009), but largely remain to be identified and characterized 
(Sorrells and Sapolsky 2007; Sorrells et al. 2009).
CNS neurotoxicity because of METH is most pronounced in the neostriatum, but damage to 
frontal, amygaloid, piriform, and parietal cortex, as well as hippocampus, has been reported 
in both mice and rats (Bowyer et al. 1994, 1998, 2004a,b, 2008; O’Callaghan and Miller 
1994; Schmued and Bowyer 1997; Eisch et al. 1998). These observations raised the 
possibility that our chronic CORT regimen would sensitize areas outside of striatum to 
mount a neuroinflammatory response to METH. The lack of an effect of METH alone on 
expression of proinflammatory mediators in frontal cortex or hippocampus is consistent with 
a lack of damage to either area with the single dosage of METH employed (20 mg/kg). In 
contrast, the emergence of neuroinflammation, microglial activation, and astrogliosis in both 
areas as a consequence of chronic CORT pre-treatment prior to METH, suggests that 
chronic CORT can make an otherwise non-vulnerable region into a target of METH 
neurotoxicity. Such effects with METH alone only are seen with much higher doses that 
result in significant blood–brain barrier damage and seizures (Bowyer and Ali 2006). 
Chronic CORT does not affect mouse brain levels of the METH analog, MDMA, given at 
high multiple doses (Johnson et al. 2004), making it unlikely to have affected METH brain 
levels in this study. Whether other areas of the CNS can be sensitized to METH damage by 
chronic CORT pre-treatment remains to be explored. The large decreases in TH and DA 
seen in striatum after pre-treatment with chronic CORT and METH, i.e., decrements 
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equivalent to those seen in mouse models of Parkinson’s disease (Jackson-Lewis and 
Przedborski 2007), were suggestive of the possibility of nigral damage. While no overt loss 
of TH-positive neurons or accompanying astrogliosis was observed, further examination of 
this region by unbiased stereological cell counts and TH and GFAP immunoassays remains 
a priority.
While the classic view of glucocorticoids is one associated with their anti-inflammatory 
properties, a proinflammatory role for these adrenal steroids is not without precedent (see 
review by Sorrells and Sapolsky 2007; Dhabhar 2009). Prior administration of CORT 
sensitizes the neuroinflammatory response to systemically administered LPS (Munhoz et al. 
2006; Frank et al. 2010). Glucocorticoids also may sensitize/prime the neuroinflammatory 
response to CNS disease and potentially chemically induced injury (Sorrells and Sapolsky 
2007). These prior observations, taken together with the present data, are suggestive of a 
role of high physiological stress in enhancing expression of proinflammatory mediators in 
the CNS because of systemic inflammogens or CNS injury. Indeed, a variety of stress 
paradigms have been shown to activate microglia (Sugama et al. 2007; Kwon et al.2008) 
and potentiate CNS proinflammatory responses (De Pablos et al. 2006; Frank et al. 2006, 
2011). Acute and chronic stress paradigms can have dramatically different effects at the 
cellular and molecular levels (Bowers et al. 2008; Dhabhar 2009). Thus, establishing any 
role for stressors and endogenous glucocorticoids in the effects we report here for exogenous 
CORT likely will require evaluation of multiple chronic stress paradigms implicated in 
priming CNS neuroinflammation (Johnson et al. 2002; Wohleb et al. 2011).
The data we have presented largely are descriptive with as yet no mechanistic 
underpinnings. Core temperature is a dominant determinant of METH-induced 
neurotoxicity, with any moderation likely influencing neurotoxic outcomes (Bowyer et al. 
1992, 1994, 1998; Miller and O’Callaghan 1994; O’Callaghan and Miller 1994; Cappon et 
al. 1996). While we have ruled out this variable in this investigation, effectors of the actions 
of both endogenous as well as exogenous glucocorticoids have yet to be explored. These 
include targets implicated in chronic stress, microglial activation, and neuroinflammation 
(Nair and Bonneau 2006; Wohleb et al. 2011) that also may influence METH-induced 
dopaminergic neurotoxicity, such glutamate and NMDA receptors (Bowyer et al. 1991, 
2004b; Nash and Yamamoto 1992; Mark et al. 2004; Brown et al. 2005; Tata and 
Yamamoto 2008; Yamamoto et al. 2010). Redistribution of cellular mediators of 
inflammation (Dhabhar 2009)and alteration in components of the toll signaling pathway 
(Watkins et al. 2009; Munhoz et al. 2010) remain as potential candidates. Nevertheless, our 
preliminary findings (Kelly et al. 2011) suggest that striatal toll receptor expression and 
activation of NF-κB, a key downstream effector in this pathway, do not play a role in the 
chronic CORT priming of METH-induced neuroinflammation. We also note that while the 
“bad actor” moniker often is associated with neuroinflammation (Watkins et al. 2007), the 
neuropoeitic/neuroinflammatory cytokine family also can play a restorative role in CNS 
injury (Bauer et al. 2007). Our findings of enhanced expression of these mediators with 
chronic CORT and METH are only associational. Moreover, our prior data showing 
suppression of METH-induced neuroinflammation without altering neurotoxicity (Sriram et 
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al. 2006) serve as an illustration of this point. Therefore, we do not yet have causal data for 
an adverse role for neuroinflammation in the enhanced neurotoxic effects of METH.
In summary, we have demonstrated that chronic administration of high physiological levels 
of CORT primes multiple areas of the CNS to mount an enhanced neuroinflammatory 
response to METH administered at a neurotoxic dose. Molecular and cellular evidence of 
enhanced METH neurotoxicity and astrogliosis also were observed. These data add to the 
view that CORT administered chronically can have a proinflammatory effect, and also show 
that such an effect can be associated with enhanced neurotoxicity.
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Chronic corticosterone (CORT) enhances methamphetamine (METH)-induced expression of 
some proinflammatory cytokines/chemokines in striatum. Acute CORT (20 mg/kg, s.c.) was 
administered 30 min prior to METH (20 mg/kg, s.c.), and chronic CORT (400 mg/L in 1.2% 
EtOH) was administered for 1 week in the drinking water prior to METH (20 mg/kg, s.c.) or 
corresponding saline (0.9%, s.c.) controls. At 12 h post METH or saline injection, mice were 
killed and total RNA was extracted from the striatum. Real-time PCR analysis was 
performed for TNF-α (a), IL-6 (b), CCL-2 (c), IL-1β (d), LIF (e), and OSM (f). Bars 
represent mean ± SEM (n = 5 mice/group). Statistical significance was measured by two-
way ANOVA with Student-Newman–Keul’s Method of post hoc analysis. Statistical 
significance of at least p < 0.05 is denoted by * as compared to control and # as compared to 
METH-treated mice.
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Chronic corticosterone (CORT) enhances methamphetamine (METH)-induced activation of 
microglia in striatum. Mice were treated with Chronic CORT for 1 week prior to METH or 
saline injection. Photomicrographs are representative images of the striatum at 20× 
magnification of Saline (a), chronic CORT (b), METH (c), and chronic CORT pre-treated 
METH (d) mice at 3 days post METH or saline injection. Scale bars: 50 μm.
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Chronic corticosterone (CORT) enhances methamphetamine (METH)-induced astrogliosis 
in striatum. Astrogliosis was quantified by Glial fibrillary acidic protein (GFAP) ELISA (a 
and b) and qualitatively demonstrated by GFAP immunostaining (c–f). (a and b) GFAP was 
assayed 3 days after either acute CORT (a) or chronic CORT (b) pre-treatment of METH-
exposed mice. Bars represent mean ± SEM (n = 5 mice/group). Statistical significance was 
measured using a one-way ANOVA with Student-Newman–Keul’s Method post hoc 
analysis for GFAP protein concentration. Statistical significance of at least p < 0.05 is 
denoted by * as compared to control and # as compared to METH-treated mice. (c–f) Mice 
were pre-treated with chronic CORT and then injected with either METH or Saline. At 3 
days post injection of METH or Saline, mice were killed and GFAP immunolabeling was 
performed. Photomicrographs are representative images of the striatum at 20× magnification 
of Saline (c), chronic CORT (d), METH (e), and chronic CORT pre-treated METH (f) mice. 
Scale bars: 50 μm.
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Chronic corticosterone (CORT) enhances methamphetamine (METH)-induced 
dopaminergic neurotoxicity in striatum. Tyrosine hydroxylase was quantified by TH ELISA 
(a and b) and qualitatively demonstrated by TH immunostaining (c–f). (a and b) TH was 
assayed 3 days after either acute CORT (a) or chronic CORT (b) pre-treatment of METH-
exposed mice. Bars represent mean ± SEM (n = 5 mice/group). Statistical significance was 
measured using a one-way ANOVA with Student-Newman–Keul’s Method post hoc 
analysis. Statistical significance of at least p < 0.05 is denoted by * as compared to control 
and # as compared to METH-treated mice. (c–f) Mice were pre-treated with chronic CORT 
followed by METH or Saline injection. At 3 days post injection of METH or Saline, mice 
were killed and TH immunolabeling was performed. Photomicrographs are representative 
images of the striatum at 2× magnification of Saline (c), chronic CORT (d), METH (e), and 
chronic CORT pre-treated METH (f) mice.
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Chronic corticosterone (CORT) sensitizes the hippocampus to methamphetamine (METH)-
induced expression of proinflammatory cytokines/chemokines. Chronic CORT (400 mg/L in 
1.2% EtOH) was administered for 1 week in the drinking water prior to METH (20 mg/kg, 
s.c.) or saline (0.9%, s.c.) exposure. At 12 h post METH or saline injection, mice were killed 
and total RNA was extracted from the hippocampus. Real-time PCR analysis was performed 
for TNF-α (a), IL-6 (b), CCL-2 (c), IL-1β (d), Leukemia inhibitory factor (LIF) (e), and 
OSM (f). Bars represent mean ± SEM (n = 5 mice/group). Statistical significance was 
measured using a two-way ANOVA with Student-Newman–Keul’s Method post hoc 
analysis. Statistical significance of at least p < 0.05 is denoted by * as compared to control 
and # as compared to METH-treated mice.
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Chronic corticosterone (CORT) sensitizes the hippocampus to methamphetamine (METH)-
induced activation of microglia. Mice were treated with chronic CORT for 1 week prior to 
METH or saline injection. Photomicrographs are representative images of Isolectin B 
staining in the hippocampus at 4× (a–d). The CA1 region of the hippocampus denoted by the 
solid box in (a) is shown at 20× magnification in (e–h). The DG region of the hippocampus 
denoted by the dotted box in (a) is shown at 20× magnification in (i–l). Scale bars: (a–d) 500 
μm and (e–l) 50 μm.
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Chronic corticosterone (CORT) sensitizes the hippocampus to methamphetamine (METH)-
induced astrogliosis. Mice were treated with chronic CORT for 1 week prior to METH or 
saline injection. Photomicrographs are representative images of Glial fibrillary acidic protein 
(GFAP) staining in the hippocampus at 4× (a–d). The CA1 region of the hippocampus 
denoted by the solid box in (a) is shown at 20× magnification in (e–h). The DG region of the 
hippocampus denoted by the dotted box in panel (a) is shown at 20× magnification in (i–l). 
Scale bars: (a–d) 500 μm and (e–l) 50 μm.
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Chronic corticosterone (CORT) sensitizes the frontal cortex to methamphetamine (METH)-
induced expression of proinflammatory cytokines/chemokines. Chronic CORT (400 mg/L in 
1.2% EtOH) was administered for 1 week in the drinking water prior to METH (20 mg/kg, 
s.c.) or saline (0.9%, s.c.) controls. At 12 h post METH or saline injection, mice were killed 
and total RNA was extracted from the frontal cortex. Real-time PCR analysis was performed 
for TNF-α (a), IL-6 (b), CCL-2 (c), IL-1β (d), Leukemia inhibitory factor (LIF) (e), and 
OSM (f). Bars represent mean ± SEM (n = 5 mice/group). Because of high variance in the 
cortex sampling, the fold changes were log transformed prior to statistical analysis. 
Statistical significance was measured using a two-way ANOVA with Student-Newman–
Keul’s Method post hoc analysis. Statistical significance of at least p < 0.05 is denoted by * 
as compared to control and # as compared to METH-treated mice.
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Chronic corticosterone (CORT) Sensitizes the Piriform Cortex to methamphetamine 
(METH)-induced Microglial Activation and Astrogliosis. Mice were treated with Chronic 
CORT for 1 week prior to METH or saline injection. Photomicrographs are representative 
images of Isolectin B (a–d) and GFAP (e–h) staining in the cortex at 20× magnification. 
Scale bars: 50 μm.
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Chronic corticosterone (CORT) does not affect methamphetamine (METH)-induced 
increase in core temperature. Rectal temperature was recorded at 0, 1, 3, 5, 7, 9, and 24 h 
after METH (20 mg/kg, s.c.) or saline (0.9%, s.c.) injection in mice pre-treated with CORT 
(400 mg/L in 1.2% EtOH) in the drinking water for 1 week. Points represent mean ± SEM (n 
= 5 mice/group). Significance was measured using two-way ANOVA with Tukey’s post hoc 
analysis. * denotes statistical significance of at least p < 0.05 when compared to control 
mice.
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